Do most antihypertensive agents have a sympatholytic action?

Current Hypertension Reports

Volumn 3, Issue 4, 2001, Pages 305-313

  De Champlain, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADRENERGIC SYSTEM; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; REVIEW;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; SYMPATHETIC NERVOUS SYSTEM;

EID: 0035430385     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0093-8     Document Type: Article

References (45)

1. Norberg KA: Transmitter histochemistry of the sympathetic adrenergic nervous system. Brain Res 1967, 5:125-170.
2. Langer SA: Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981, 32:337-362.
3. Raymond JR, Hnatowich M, Lefkowitz R.J., Caron MG: Adrenergic receptors: models for regulation of signal transduction processes. Hypertension 1990, 15:119-131.
4. Berridge MJ: Inositol triphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987, 56:159-163.
5. Grassi G, Cattaneo BM, Seravalle G, et al: Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998, 31:68-72.
6. Julius S: The blood pressure seeking properties of the central nervous system. J Hypertens 1988, 6:177-185.
7. Goldstein DS: Plasma catecholamines and essential hypertension: an analytical review. Hypertension 1983, 5:86-89.
8. Esler M, Jenning G, Korner P., et al.: Assessment of human sympathetic nervous system activity from measurement of nore-pinephrine turnover. Hypertension 1988, 11: 3-20.
9. Grassi G, Bolla GB, Saravalle G, et al: Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci 1997, 92:285-189.
10. Feldman RD: b-adrenergic receptor alteration in hypertension: physiological and molecular correlates. Can J Physiol Pharmacol 1987, 64:1666-1672.
11. de Champlain J: Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens 1990, 8 (suppl 7):S77-S85.
12. de Champlain J., Petrovich M, Gonzalez M., et al.: Abnormal cardiovascular reactivity in borderline and mild essential hypertension. Hypertension 1991, 17 (suppl III):22-28.
13. Gros R, Chorazyczweski J, Meek M.D., et al.: G-protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 2000, 35:38-42.
14. Liang C, Rounds NK, Dong E, et al.: Alterations by norepinephrine of cardiac sympathetic nerve terminal function and myocardial b-adrenergic receptor sensitivity in the ferret. Normalisation by antioxidant vitamins. Circulation 2000, 102: 96-103.
15. Dhalla NS, Temsah RM, Netticadan T: Role of oxidative stress in cardiovascular diseases. J Hypertens 2000, 18:655-673.
16. Wu R, Millette E, Wu L., de Champlain J: Enhanced superoxide anion formation in vascular tissues from SHR and DOCA-salt hypertensive rats. J Hypertens 2001, 19:741-748.
17. Rajagopalan S, Kurz S, Munzel T., et al.: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996, 97(8):1916-1923.
18. Wu L, de Champlain J: Effects of superoxide on signaling pathways in smooth muscle cells from rats. Hypertension 1999, 34:1247-1253.
19. Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens 1997, 15:1-15.
20. Levy D, Garrison RJ, Savage D.D., et al.: Prognosis implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
21. Brush JE, Cannon RO, Schenkewh W.H., et al.: Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1998, 319:1302-1307.
22. Facchini FS, Stoohs RA, Reaven GM: Enhanced sympathetic system activity. The linchpin between insulin resistance, hyperinsulinemia and heart rate. Am J Hypentens 1996, 9:1013-1017.
23. De Fronzo R.A., Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
24. Cohn JN: Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci 1966, 30:267-278.
25. Kjeldsen SE, Gjesdal K. Eide I, et al.: Increased beta thrombo-globulin in essential hypertension: interactions between arterial plasma adrenaline, platelet function and blood lipid. Acta Med Scand 1983, 213:369-373.
26. K-Laflamme A, de Champlain J: Interactions des systèmes sympathique et cardiovasculaire. Thérapie 1998, 53:245-252.
27. K-Laflamme A, Oster L., Cardinal R, de Champlain J: Effects of renin-angiotensin blockade on the sympathetic reactivity and b-adrenergic pathway in the spontaneously hypertensive rat. J Hypertens 1997, 30:278-287.
28. Bing R.F., Thusrton H, Swales JD Salt-intake and diuretic treatment of hypertension. Lancet 1979, 2:121-123.
29. Chernow B, Zaloga GP, Lake C.R., et al.: Effect of antihypertensive therapy on sympathetic nervous system activity in patients with essential hypertension. Fed Proc 1984, 43:72-77.
30. Calder JA, Schachter M, Sever PS: Direct vascular action of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol 1992, 220:19-26.
31. Pickers P, Garcha RS, Schachter M, et al: Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension 1999, 33:1043-1048.
32. de Champlain J., Cousineau D, Lapointe L: Evidence supporting an increased sympathetic tone and reactivity in a subgroup of patients with essential hypertension. Clin Exp Hypertens [A] 1980, 2:359-377.
33. Guan YY, Kwan CY, Daniel EE Evidence against the role of alpha1-adrenoceptor reserve in buffering the inhibitory effect of nifedipine on the contractility of canine vascular smooth muscle. Can J Physiol Pharmacol 1990, 68:1346-1360.
34. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975.
35. Kobinger W: Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem 1978, 91:39-100.
36. Grossman E, Messerli FH: Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am J Cardiol 1997, 80:1453-1458.
37. de Champlain J., Karas M, Nguyen P., et al.: Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998, 16(9):1357-1369.
38. Pedrinelli R, Taddei S, Salvetti A: Calcium entry blockade and selective alpha-adrenergic stimulation in animals and man. J Cardiovasc Pharmacol 1987, 10: 79-86.
39. Pedrinelli R, Taddei S, Panarance G., et al.: Calcium entry blockade and agonist mediated vasoconstriction in hypertensive patients. J Cardiovasc Pharmacol 1990, 16:34-39.
40. Gaspo R, Yamaguchi N, de Champlain J: Effects of nifedipine and BAY K 8644 on stimulation-induced adrenal catechola-mine secretion in the dog. Am J Physiol 1993, 265:R28-R34.
41. Giannattasio C, Cattaneo BM, Omboni S, et al: Sympatho-moderating influence of benazepril in essential hypertension. J Hypertens 1992, 10: 373-378.
42. de Champlain J., Yacine A, LeBlanc R., et al.: Effects of trandola-pril on the sympathetic tone and reactivity in hypertensive patients. Am J Cardiol 1994, 73:18C-25C.
43. Ligtenberg G, Blankestijn PJ, Oey L, et al: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340:1231-1328.
44. Grassi G, Cattaneo BM, Seravalle G, et al: Effect of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997, 96:1173-1179.
45. de Champlain J: Participation du système nerveux autonome dans l'hypertension artérielle. Médecine/Sciences 1998, 14:(suppl 2):10-22.